Secondary Prevention of Venous Thrombo Embolism (VTE). (RE-MEDY)
2014年5月8日 更新者:Boehringer Ingelheim
A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.
調査の概要
研究の種類
介入
入学 (実際)
2867
段階
- フェーズ 3
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Alabama
-
Mobile、Alabama、アメリカ
- 1160.47.01035 Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
Hartford、Connecticut、アメリカ
- 1160.47.01056 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Clearwater、Florida、アメリカ
- 1160.47.01044 Boehringer Ingelheim Investigational Site
-
-
Georgia
-
Augusta、Georgia、アメリカ
- 1160.47.01019 Boehringer Ingelheim Investigational Site
-
Decatur、Georgia、アメリカ
- 1160.47.01008 Boehringer Ingelheim Investigational Site
-
-
Maryland
-
Baltimore、Maryland、アメリカ
- 1160.47.01014 Boehringer Ingelheim Investigational Site
-
-
Massachusetts
-
Roxbury Crossing、Massachusetts、アメリカ
- 1160.47.01018 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Detroit、Michigan、アメリカ
- 1160.47.01023 Boehringer Ingelheim Investigational Site
-
-
Minnesota
-
St. Louis Park、Minnesota、アメリカ
- 1160.47.01009 Boehringer Ingelheim Investigational Site
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ
- 1160.47.01031 Boehringer Ingelheim Investigational Site
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ
- 1160.47.01036 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ
- 1160.47.01027 Boehringer Ingelheim Investigational Site
-
Winston-Salem、North Carolina、アメリカ
- 1160.47.01039 Boehringer Ingelheim Investigational Site
-
-
North Dakota
-
Grand Forks、North Dakota、アメリカ
- 1160.47.01030 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Toledo、Ohio、アメリカ
- 1160.47.01013 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Altoona、Pennsylvania、アメリカ
- 1160.47.01052 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Summerville、South Carolina、アメリカ
- 1160.47.01055 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Richmond、Virginia、アメリカ
- 1160.47.01017 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Adrogué、アルゼンチン
- 1160.47.54017 Boehringer Ingelheim Investigational Site
-
Bahía Blanca、アルゼンチン
- 1160.47.54015 Boehringer Ingelheim Investigational Site
-
Capital Federal、アルゼンチン
- 1160.47.54001 Boehringer Ingelheim Investigational Site
-
Capital Federal、アルゼンチン
- 1160.47.54003 Boehringer Ingelheim Investigational Site
-
Capital Federal、アルゼンチン
- 1160.47.54005 Boehringer Ingelheim Investigational Site
-
Capital Federal、アルゼンチン
- 1160.47.54006 Boehringer Ingelheim Investigational Site
-
Capital Federal、アルゼンチン
- 1160.47.54007 Boehringer Ingelheim Investigational Site
-
Capital Federal、アルゼンチン
- 1160.47.54010 Boehringer Ingelheim Investigational Site
-
La Plata、アルゼンチン
- 1160.47.54016 Boehringer Ingelheim Investigational Site
-
Mar del Plata、アルゼンチン
- 1160.47.54014 Boehringer Ingelheim Investigational Site
-
Quilmes、アルゼンチン
- 1160.47.54013 Boehringer Ingelheim Investigational Site
-
Rosario、アルゼンチン
- 1160.47.54011 Boehringer Ingelheim Investigational Site
-
Salta、アルゼンチン
- 1160.47.54018 Boehringer Ingelheim Investigational Site
-
Santa Fe、アルゼンチン
- 1160.47.54012 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Headington, Oxford、イギリス
- 1160.47.44005 Boehringer Ingelheim Investigational Site
-
London、イギリス
- 1160.47.44009 Boehringer Ingelheim Investigational Site
-
London、イギリス
- 1160.47.44011 Boehringer Ingelheim Investigational Site
-
Newcastle upon Tyne、イギリス
- 1160.47.44006 Boehringer Ingelheim Investigational Site
-
Sheffield、イギリス
- 1160.47.44012 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Afula、イスラエル
- 1160.47.97202 Boehringer Ingelheim Investigational Site
-
Ashkelon、イスラエル
- 1160.47.97207 Boehringer Ingelheim Investigational Site
-
Haifa、イスラエル
- 1160.47.97211 Boehringer Ingelheim Investigational Site
-
Holon、イスラエル
- 1160.47.97203 Boehringer Ingelheim Investigational Site
-
Kfar Saba、イスラエル
- 1160.47.97205 Boehringer Ingelheim Investigational Site
-
Petach Tikva、イスラエル
- 1160.47.97206 Boehringer Ingelheim Investigational Site
-
Rehovot、イスラエル
- 1160.47.97208 Boehringer Ingelheim Investigational Site
-
Tel Aviv、イスラエル
- 1160.47.97210 Boehringer Ingelheim Investigational Site
-
Tel Hashomer、イスラエル
- 1160.47.97204 Boehringer Ingelheim Investigational Site
-
Zerifin、イスラエル
- 1160.47.97201 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bologna、イタリア
- 1160.47.39003 Boehringer Ingelheim Investigational Site
-
Cremona、イタリア
- 1160.47.39004 Boehringer Ingelheim Investigational Site
-
Genova、イタリア
- 1160.47.39006 Boehringer Ingelheim Investigational Site
-
Milano、イタリア
- 1160.47.39008 Boehringer Ingelheim Investigational Site
-
Reggio Emilia、イタリア
- 1160.47.39007 Boehringer Ingelheim Investigational Site
-
Udine、イタリア
- 1160.47.39009 Boehringer Ingelheim Investigational Site
-
Vittorio Veneto、イタリア
- 1160.47.39005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Ahmedabad、インド
- 1160.47.91002 Boehringer Ingelheim Investigational Site
-
Bangalore、インド
- 1160.47.91011 Boehringer Ingelheim Investigational Site
-
Bangalore、インド
- 1160.47.91015 Boehringer Ingelheim Investigational Site
-
Chennai、インド
- 1160.47.91012 Boehringer Ingelheim Investigational Site
-
Chennai、インド
- 1160.47.91017 Boehringer Ingelheim Investigational Site
-
Madurai、インド
- 1160.47.91009 Boehringer Ingelheim Investigational Site
-
Mysore、インド
- 1160.47.91007 Boehringer Ingelheim Investigational Site
-
New Delhi、インド
- 1160.47.91003 Boehringer Ingelheim Investigational Site
-
New Delhi、インド
- 1160.47.91010 Boehringer Ingelheim Investigational Site
-
Pune、インド
- 1160.47.91001 Boehringer Ingelheim Investigational Site
-
Pune、インド
- 1160.47.91005 Boehringer Ingelheim Investigational Site
-
Pune、インド
- 1160.47.91008 Boehringer Ingelheim Investigational Site
-
Trivandrum、インド
- 1160.47.91014 Boehringer Ingelheim Investigational Site
-
Vadodara、インド
- 1160.47.91004 Boehringer Ingelheim Investigational Site
-
new Delhi、インド
- 1160.47.91006 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kharkov、ウクライナ
- 1160.47.38002 Boehringer Ingelheim Investigational Site
-
Kiev、ウクライナ
- 1160.47.38006 Boehringer Ingelheim Investigational Site
-
Vinnitsa、ウクライナ
- 1160.47.38005 Boehringer Ingelheim Investigational Site
-
Zaporozhye、ウクライナ
- 1160.47.38003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Amersfoort、オランダ
- 1160.47.31001 Boehringer Ingelheim Investigational Site
-
Amsterdam、オランダ
- 1160.47.31006 Boehringer Ingelheim Investigational Site
-
Amsterdam、オランダ
- 1160.47.31007 Boehringer Ingelheim Investigational Site
-
Den Bosch、オランダ
- 1160.47.31010 Boehringer Ingelheim Investigational Site
-
Heerlen、オランダ
- 1160.47.31014 Boehringer Ingelheim Investigational Site
-
Maastricht、オランダ
- 1160.47.31005 Boehringer Ingelheim Investigational Site
-
Rotterdam、オランダ
- 1160.47.31004 Boehringer Ingelheim Investigational Site
-
Rotterdam、オランダ
- 1160.47.31009 Boehringer Ingelheim Investigational Site
-
-
-
-
Queensland
-
Wooloongabba、Queensland、オーストラリア
- 1160.47.61002 Princess Alexandra Hospital
-
-
South Australia
-
Bedford Park、South Australia、オーストラリア
- 1160.47.61004 Boehringer Ingelheim Investigational Site
-
-
Victoria
-
Box Hill、Victoria、オーストラリア
- 1160.47.61003 Boehringer Ingelheim Investigational Site
-
Clayton、Victoria、オーストラリア
- 1160.47.61001 Boehringer Ingelheim Investigational Site
-
Windsor、Victoria、オーストラリア
- 1160.47.61006 Boehringer Ingelheim Investigational Site
-
-
Western Australia
-
Perth、Western Australia、オーストラリア
- 1160.47.61005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Graz、オーストリア
- 1160.47.43001 Boehringer Ingelheim Investigational Site
-
Innsbruck、オーストリア
- 1160.47.43003 Boehringer Ingelheim Investigational Site
-
Wien、オーストリア
- 1160.47.43002 Boehringer Ingelheim Investigational Site
-
Wien、オーストリア
- 1160.47.43004 Boehringer Ingelheim Investigational Site
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ
- 1160.47.02006 Boehringer Ingelheim Investigational Site
-
Edmonton、Alberta、カナダ
- 1160.47.02013 Boehringer Ingelheim Investigational Site
-
-
British Columbia
-
Victoria、British Columbia、カナダ
- 1160.47.02021 Boehringer Ingelheim Investigational Site
-
-
New Brunswick
-
Saint Johns、New Brunswick、カナダ
- 1160.47.02004 Boehringer Ingelheim Investigational Site
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ
- 1160.47.02001 Boehringer Ingelheim Investigational Site
-
-
Ontario
-
Hamilton、Ontario、カナダ
- 1160.47.02002 Boehringer Ingelheim Investigational Site
-
Hamilton、Ontario、カナダ
- 1160.47.02005 Boehringer Ingelheim Investigational Site
-
Hamilton、Ontario、カナダ
- 1160.47.02010 Boehringer Ingelheim Investigational Site
-
Hamilton、Ontario、カナダ
- 1160.47.02022 Boehringer Ingelheim Investigational Site
-
Ottawa、Ontario、カナダ
- 1160.47.02015 Boehringer Ingelheim Investigational Site
-
Toronto、Ontario、カナダ
- 1160.47.02019 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Montreal、Quebec、カナダ
- 1160.47.02008 Boehringer Ingelheim Investigational Site
-
Montreal、Quebec、カナダ
- 1160.47.02009 Boehringer Ingelheim Investigational Site
-
Montreal、Quebec、カナダ
- 1160.47.02014 Boehringer Ingelheim Investigational Site
-
Montreal、Quebec、カナダ
- 1160.47.02017 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Athens、ギリシャ
- 1160.47.30001 Boehringer Ingelheim Investigational Site
-
Athens、ギリシャ
- 1160.47.30006 Boehringer Ingelheim Investigational Site
-
Athens、ギリシャ
- 1160.47.30007 Boehringer Ingelheim Investigational Site
-
Athens、ギリシャ
- 1160.47.30009 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Göteborg、スウェーデン
- 1160.47.46002 Boehringer Ingelheim Investigational Site
-
Jönköping、スウェーデン
- 1160.47.46006 Boehringer Ingelheim Investigational Site
-
Stockholm、スウェーデン
- 1160.47.46001 Boehringer Ingelheim Investigational Site
-
Stockholm、スウェーデン
- 1160.47.46007 Boehringer Ingelheim Investigational Site
-
Stockholm、スウェーデン
- 1160.47.46008 Boehringer Ingelheim Investigational Site
-
Sundsvall、スウェーデン
- 1160.47.46005 Boehringer Ingelheim Investigational Site
-
Uppsala、スウェーデン
- 1160.47.46003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Alicante、スペイン
- 1160.47.34006 Boehringer Ingelheim Investigational Site
-
Badalona (Barcelona)、スペイン
- 1160.47.34012 Boehringer Ingelheim Investigational Site
-
Barcelona、スペイン
- 1160.47.34001 Boehringer Ingelheim Investigational Site
-
Barcelona、スペイン
- 1160.47.34002 Boehringer Ingelheim Investigational Site
-
Cartagena. Murcia、スペイン
- 1160.47.34007 Boehringer Ingelheim Investigational Site
-
Cuenca、スペイン
- 1160.47.34003 Boehringer Ingelheim Investigational Site
-
Madrid、スペイン
- 1160.47.34009 Boehringer Ingelheim Investigational Site
-
Santander、スペイン
- 1160.47.34004 Boehringer Ingelheim Investigational Site
-
Valencia、スペイン
- 1160.47.34011 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Banska Bystrica、スロバキア
- 1160.47.42107 Boehringer Ingelheim Investigational Site
-
Lucenec、スロバキア
- 1160.47.42106 Boehringer Ingelheim Investigational Site
-
Nitra、スロバキア
- 1160.47.42102 Boehringer Ingelheim Investigational Site
-
Nove Zamky、スロバキア
- 1160.47.42103 Boehringer Ingelheim Investigational Site
-
Zilina、スロバキア
- 1160.47.42104 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Brno、チェコ共和国
- 1160.47.42001 Boehringer Ingelheim Investigational Site
-
Hradec Kralove、チェコ共和国
- 1160.47.42002 Boehringer Ingelheim Investigational Site
-
Hranice、チェコ共和国
- 1160.47.42011 Boehringer Ingelheim Investigational Site
-
Liberec、チェコ共和国
- 1160.47.42012 Boehringer Ingelheim Investigational Site
-
Novy Jicin、チェコ共和国
- 1160.47.42015 Boehringer Ingelheim Investigational Site
-
Ostrava-Vitkovice、チェコ共和国
- 1160.47.42005 Boehringer Ingelheim Investigational Site
-
Praha 2、チェコ共和国
- 1160.47.42004 Boehringer Ingelheim Investigational Site
-
Tabor、チェコ共和国
- 1160.47.42014 Boehringer Ingelheim Investigational Site
-
Usti nad Labem、チェコ共和国
- 1160.47.42010 Boehringer Ingelheim Investigational Site
-
Zlin、チェコ共和国
- 1160.47.42007 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Esbjerg、デンマーク
- 1160.47.45008 Boehringer Ingelheim Investigational Site
-
Holbæk、デンマーク
- 1160.47.45009 Boehringer Ingelheim Investigational Site
-
Kolding、デンマーク
- 1160.47.45002 Boehringer Ingelheim Investigational Site
-
København NV、デンマーク
- 1160.47.45004 Boehringer Ingelheim Investigational Site
-
København S、デンマーク
- 1160.47.45007 Boehringer Ingelheim Investigational Site
-
Slagelse、デンマーク
- 1160.47.45006 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Dresden、ドイツ
- 1160.47.49017 Boehringer Ingelheim Investigational Site
-
Dresden、ドイツ
- 1160.47.49018 Boehringer Ingelheim Investigational Site
-
Köln、ドイツ
- 1160.47.49003 Boehringer Ingelheim Investigational Site
-
Mannheim、ドイツ
- 1160.47.49005 Boehringer Ingelheim Investigational Site
-
Mannheim、ドイツ
- 1160.47.49006 Boehringer Ingelheim Investigational Site
-
München、ドイツ
- 1160.47.49007 Boehringer Ingelheim Investigational Site
-
München、ドイツ
- 1160.47.49008 Boehringer Ingelheim Investigational Site
-
Püttlingen、ドイツ
- 1160.47.49009 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Christchurch、ニュージーランド
- 1160.47.64004 Boehringer Ingelheim Investigational Site
-
Grafton、ニュージーランド
- 1160.47.64003 Boehringer Ingelheim Investigational Site
-
Otahuhu、ニュージーランド
- 1160.47.64002 Boehringer Ingelheim Investigational Site
-
Takapuna Auckland 9、ニュージーランド
- 1160.47.64001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Oslo、ノルウェー
- 1160.47.47001 Boehringer Ingelheim Investigational Site
-
Oslo、ノルウェー
- 1160.47.47004 Boehringer Ingelheim Investigational Site
-
Rud、ノルウェー
- 1160.47.47003 Boehringer Ingelheim Investigational Site
-
Trondheim、ノルウェー
- 1160.47.47005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Budapest、ハンガリー
- 1160.47.36001 Boehringer Ingelheim Investigational Site
-
Budapest、ハンガリー
- 1160.47.36006 Boehringer Ingelheim Investigational Site
-
Budapest、ハンガリー
- 1160.47.36007 Boehringer Ingelheim Investigational Site
-
Debrecen、ハンガリー
- 1160.47.36002 Boehringer Ingelheim Investigational Site
-
Gyula、ハンガリー
- 1160.47.36012 Boehringer Ingelheim Investigational Site
-
Miskolc、ハンガリー
- 1160.47.36004 Boehringer Ingelheim Investigational Site
-
Pecs、ハンガリー
- 1160.47.36003 Boehringer Ingelheim Investigational Site
-
Szombathely、ハンガリー
- 1160.47.36011 Boehringer Ingelheim Investigational Site
-
Székesfehérvár、ハンガリー
- 1160.47.36010 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Espoo、フィンランド
- 1160.47.35804 Boehringer Ingelheim Investigational Site
-
Helsinki、フィンランド
- 1160.47.35801 Boehringer Ingelheim Investigational Site
-
Jyväskylä、フィンランド
- 1160.47.35802 Boehringer Ingelheim Investigational Site
-
Kuopio、フィンランド
- 1160.47.35805 Boehringer Ingelheim Investigational Site
-
Tampere、フィンランド
- 1160.47.35803 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Brest Cedex、フランス
- 1160.47.3301A Boehringer Ingelheim Investigational Site
-
Brest Cedex、フランス
- 1160.47.3301B Boehringer Ingelheim Investigational Site
-
Brest Cedex、フランス
- 1160.47.3301C Boehringer Ingelheim Investigational Site
-
Brest Cedex、フランス
- 1160.47.3301D Boehringer Ingelheim Investigational Site
-
Brest Cedex、フランス
- 1160.47.3301E Boehringer Ingelheim Investigational Site
-
Brest Cedex、フランス
- 1160.47.3301F Boehringer Ingelheim Investigational Site
-
Brest Cedex、フランス
- 1160.47.3301H Boehringer Ingelheim Investigational Site
-
Brest Cedex、フランス
- 1160.47.3301I Boehringer Ingelheim Investigational Site
-
Lorient、フランス
- 1160.47.3302A Boehringer Ingelheim Investigational Site
-
St Etienne Cedex 2、フランス
- 1160.47.3303A Boehringer Ingelheim Investigational Site
-
St Etienne Cedex 2、フランス
- 1160.47.3303B Boehringer Ingelheim Investigational Site
-
St Etienne Cedex 2、フランス
- 1160.47.3303C Boehringer Ingelheim Investigational Site
-
St Etienne Cedex 2、フランス
- 1160.47.3303D Boehringer Ingelheim Investigational Site
-
Vandoeuvre les Nancy、フランス
- 1160.47.3308A Boehringer Ingelheim Investigational Site
-
-
-
-
-
Brasília、ブラジル
- 1160.47.55010 Boehringer Ingelheim Investigational Site
-
Campinas - SP、ブラジル
- 1160.47.55007 Boehringer Ingelheim Investigational Site
-
Curitiba、ブラジル
- 1160.47.55014 Boehringer Ingelheim Investigational Site
-
Juvene - Paraná -、ブラジル
- 1160.47.55017 Boehringer Ingelheim Investigational Site
-
Rio de Janeiro - RJ、ブラジル
- 1160.47.55016 Boehringer Ingelheim Investigational Site
-
São Bernardo do Campo、ブラジル
- 1160.47.55018 Boehringer Ingelheim Investigational Site
-
São José do Rio Preto、ブラジル
- 1160.47.55005 Boehringer Ingelheim Investigational Site
-
pTO aLEGRE、ブラジル
- 1160.47.55012 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Plovdiv、ブルガリア
- 1160.47.35910 Boehringer Ingelheim Investigational Site
-
Rousse、ブルガリア
- 1160.47.35908 Boehringer Ingelheim Investigational Site
-
Sofia、ブルガリア
- 1160.47.35901 Boehringer Ingelheim Investigational Site
-
Sofia、ブルガリア
- 1160.47.35903 Boehringer Ingelheim Investigational Site
-
Sofia、ブルガリア
- 1160.47.35904 Boehringer Ingelheim Investigational Site
-
Sofia、ブルガリア
- 1160.47.35906 Boehringer Ingelheim Investigational Site
-
Sofia、ブルガリア
- 1160.47.35907 Boehringer Ingelheim Investigational Site
-
Varna、ブルガリア
- 1160.47.35905 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bruxelles、ベルギー
- 1160.47.32001 Boehringer Ingelheim Investigational Site
-
Bruxelles、ベルギー
- 1160.47.32002 Boehringer Ingelheim Investigational Site
-
Leuven、ベルギー
- 1160.47.32005 Boehringer Ingelheim Investigational Site
-
Liège、ベルギー
- 1160.47.32004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Almada、ポルトガル
- 1160.47.35104 Boehringer Ingelheim Investigational Site
-
Coimbra、ポルトガル
- 1160.47.35109 Boehringer Ingelheim Investigational Site
-
Covilhã、ポルトガル
- 1160.47.35107 Boehringer Ingelheim Investigational Site
-
Lisboa、ポルトガル
- 1160.47.35101 Boehringer Ingelheim Investigational Site
-
Lisboa、ポルトガル
- 1160.47.35102 Boehringer Ingelheim Investigational Site
-
Lisboa、ポルトガル
- 1160.47.35105 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kielce、ポーランド
- 1160.47.48004 Boehringer Ingelheim Investigational Site
-
Krakow、ポーランド
- 1160.47.48005 Boehringer Ingelheim Investigational Site
-
Krakow、ポーランド
- 1160.47.48007 Boehringer Ingelheim Investigational Site
-
Poznan、ポーランド
- 1160.47.48003 Boehringer Ingelheim Investigational Site
-
Warsaw、ポーランド
- 1160.47.48006 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Chihuahua、メキシコ
- 1160.47.52036 Boehringer Ingelheim Investigational Site
-
Culiacan、メキシコ
- 1160.47.52039 Boehringer Ingelheim Investigational Site
-
Guadalajara, Jal.、メキシコ
- 1160.47.52030 Boehringer Ingelheim Investigational Site
-
Monterrey、メキシコ
- 1160.47.52027 Boehringer Ingelheim Investigational Site
-
San Luis Potosí、メキシコ
- 1160.47.52034 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Belgorod、ロシア連邦
- 1160.47.07022 Boehringer Ingelheim Investigational Site
-
Chelyabinsk、ロシア連邦
- 1160.47.07011 Boehringer Ingelheim Investigational Site
-
Chelyabinsk、ロシア連邦
- 1160.47.07021 Boehringer Ingelheim Investigational Site
-
Ekaterinburg、ロシア連邦
- 1160.47.07007 Boehringer Ingelheim Investigational Site
-
Krasnodar、ロシア連邦
- 1160.47.07016 Boehringer Ingelheim Investigational Site
-
Kursk、ロシア連邦
- 1160.47.07004 Boehringer Ingelheim Investigational Site
-
Novosibirsk、ロシア連邦
- 1160.47.07010 Boehringer Ingelheim Investigational Site
-
Omsk、ロシア連邦
- 1160.47.07020 Boehringer Ingelheim Investigational Site
-
Pskov、ロシア連邦
- 1160.47.07018 Boehringer Ingelheim Investigational Site
-
Rostov-na-Donu、ロシア連邦
- 1160.47.07009 Boehringer Ingelheim Investigational Site
-
Rostov-na-Donu、ロシア連邦
- 1160.47.07023 Boehringer Ingelheim Investigational Site
-
Rostov-na-Donu、ロシア連邦
- 1160.47.07024 Boehringer Ingelheim Investigational Site
-
Rostov-na-Donu、ロシア連邦
- 1160.47.07025 Boehringer Ingelheim Investigational Site
-
St. Petersburg、ロシア連邦
- 1160.47.07001 Boehringer Ingelheim Investigational Site
-
St. Petersburg、ロシア連邦
- 1160.47.07002 Boehringer Ingelheim Investigational Site
-
St. Petersburg、ロシア連邦
- 1160.47.07017 Boehringer Ingelheim Investigational Site
-
Tyumen、ロシア連邦
- 1160.47.07019 Boehringer Ingelheim Investigational Site
-
Ufa、ロシア連邦
- 1160.47.07014 Boehringer Ingelheim Investigational Site
-
Yaroslavl、ロシア連邦
- 1160.47.07005 Boehringer Ingelheim Investigational Site
-
Yaroslavl、ロシア連邦
- 1160.47.07006 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Ankara、七面鳥
- 1160.47.90003 Boehringer Ingelheim Investigational Site
-
Ankara、七面鳥
- 1160.47.90004 Boehringer Ingelheim Investigational Site
-
Ankara、七面鳥
- 1160.47.90005 Boehringer Ingelheim Investigational Site
-
Istanbul、七面鳥
- 1160.47.90001 Boehringer Ingelheim Investigational Site
-
Istanbul、七面鳥
- 1160.47.90002 Boehringer Ingelheim Investigational Site
-
Istanbul、七面鳥
- 1160.47.90007 Boehringer Ingelheim Investigational Site
-
Izmir、七面鳥
- 1160.47.90006 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Beijing、中国
- 1160.47.86001 Boehringer Ingelheim Investigational Site
-
Beijing、中国
- 1160.47.86015 Boehringer Ingelheim Investigational Site
-
Chengdu、中国
- 1160.47.86014 Boehringer Ingelheim Investigational Site
-
Guangzhou、中国
- 1160.47.86012 Boehringer Ingelheim Investigational Site
-
Hangzhou、中国
- 1160.47.86009 Boehringer Ingelheim Investigational Site
-
Hangzhou、中国
- 1160.47.86010 Boehringer Ingelheim Investigational Site
-
Nanjing、中国
- 1160.47.86013 Boehringer Ingelheim Investigational Site
-
Shanghai、中国
- 1160.47.86002 Boehringer Ingelheim Investigational Site
-
Shanghai、中国
- 1160.47.86003 Boehringer Ingelheim Investigational Site
-
Shanghai、中国
- 1160.47.86004 Boehringer Ingelheim Investigational Site
-
Shanghai、中国
- 1160.47.86005 Boehringer Ingelheim Investigational Site
-
Shanghai、中国
- 1160.47.86006 Boehringer Ingelheim Investigational Site
-
Shanghai、中国
- 1160.47.86007 Boehringer Ingelheim Investigational Site
-
Shanghai、中国
- 1160.47.86016 Boehringer Ingelheim Investigational Site
-
Shijiazhuang、中国
- 1160.47.86011 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Johannesburg、南アフリカ
- 1160.47.27001 Boehringer Ingelheim Investigational Site
-
Johannesburg、南アフリカ
- 1160.47.27002 Boehringer Ingelheim Investigational Site
-
Johannesburg、南アフリカ
- 1160.47.27006 Boehringer Ingelheim Investigational Site
-
Pretoria、南アフリカ
- 1160.47.27007
-
Randburg、南アフリカ
- 1160.47.27003 Boehringer Ingelheim Investigational Site
-
Roodepoort、南アフリカ
- 1160.47.27005 Boehringer Ingelheim Investigational Site
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion criteria:
Inclusion_Criteria
- Acute symptomatic deep vein thrombosis (DVT)
- Pulmonary embolism (PE) 3-12 months prior to screening, which has been documented by objective testing
Exclusion criteria:
Exclusion_Criteria
- Symptomatic DVT or PE at screening Interruption of anticoagulant therapy for 2 or more weeks during the 3-12 months of treatment for the prior VTE.
- Patients who in the investigators judgement are perceived as having an excessive risk of bleeding Elevated Aspartate aminotransferase (AST) or Alanine tranminase (ALT) > 2x ULN
- Severe renal impairment (estimated creatinine clearance <= 30 ml/min)
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dabigatran
Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
|
Dabigatran 150 mg BID (twice daily)
|
|
アクティブコンパレータ:Warfarin (INR of 2.0-3.0)
Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
|
Warfarin dosed individually to maintain INR 2.0-3.0
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite of Recurrent VTE or VTE Death at 36 Months
時間枠:36 months
|
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE.
VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE).
All recurrent VTEs required objective verification by definitive diagnostic evaluation.
In case of death, autopsy was an additional way to confirm VTE.
|
36 months
|
|
Composite of Recurrent VTE or VTE Death at 18 Months
時間枠:18 months
|
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE.
VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE).
All recurrent VTEs required objective verification by definitive diagnostic evaluation.
In case of death, autopsy was an additional way to confirm VTE.
|
18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite of Recurrent VTE or All Cause Death at 36 Months
時間枠:36 months
|
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death.
VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE).
All recurrent VTEs required objective verification by definitive diagnostic evaluation.
|
36 months
|
|
Composite of Recurrent VTE or All Cause Death at 18 Months
時間枠:18 months
|
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death.
VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE).
All recurrent VTEs required objective verification by definitive diagnostic evaluation.
|
18 months
|
|
Deep Vein Thrombosis (DVT) at 36 Months
時間枠:36 months
|
Symptomatic Deep vein thrombosis (DVT).
All DVT events required objective verification through definitive diagnostic evaluation.
|
36 months
|
|
DVT at 18 Months
時間枠:18 months
|
Symptomatic Deep vein thrombosis (DVT).
All DVT events required objective verification through definitive diagnostic evaluation.
|
18 months
|
|
Symptomatic Pulmonary Embolism (PE) at 36 Months
時間枠:36 months
|
Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal).
All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.
|
36 months
|
|
Symptomatic Pulmonary Embolism (PE) at 18 Months
時間枠:18 months
|
Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal).
All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.
|
18 months
|
|
Deaths Related to VTE at 36 Months
時間枠:36 months
|
Deaths related to VTE (i.e.
fatal PE) at 36 Months.
Deaths related to VTE (i.e.
fatal PE) at 18 Months.
All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.
|
36 months
|
|
Deaths Related to VTE at 18 Months
時間枠:18 months
|
Deaths related to VTE (i.e.
fatal PE) at 18 Months.
All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.
|
18 months
|
|
Deaths of All Causes at 36 Months
時間枠:36 months
|
Deaths of all causes at 36 Months.
All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.
|
36 months
|
|
Deaths of All Causes at 18 Months
時間枠:18 months
|
Deaths of all causes at 18 Months.
All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.
|
18 months
|
|
Number of Participants With Bleeding Events
時間枠:first intake of study drug until 6 days following last intake of study drug
|
MBE (major bleeding event) if it fulfilled at least one of the following criteria
Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria
|
first intake of study drug until 6 days following last intake of study drug
|
|
Laboratory Analysis
時間枠:18 months + 30 days follow up
|
Patients with LFT (liver function tests) increases of possible clinical significance during treatment.
Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin).
Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality).
|
18 months + 30 days follow up
|
|
Number of Participants With Definite Acute Coronary Syndrome (ACS)
時間枠:day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination
|
All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner.
|
day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
一般刊行物
- Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013 Nov 19;128(21):2325-32. doi: 10.1161/CIRCULATIONAHA.113.002332. Epub 2013 Sep 30.
- Goldhaber SZ, Eriksson H, Kakkar A, Schellong S, Feuring M, Fraessdorf M, Kreuzer J, Schueler E, Schulman S. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER(R), RE-COVER II, and RE-MEDY. Vasc Med. 2016 Dec;21(6):506-514. doi: 10.1177/1358863X16668588. Epub 2016 Nov 1.
- Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18. doi: 10.1056/NEJMoa1113697.
便利なリンク
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2006年5月1日
一次修了 (実際)
2010年10月1日
試験登録日
最初に提出
2006年5月23日
QC基準を満たした最初の提出物
2006年5月23日
最初の投稿 (見積もり)
2006年5月24日
学習記録の更新
投稿された最後の更新 (見積もり)
2014年5月19日
QC基準を満たした最後の更新が送信されました
2014年5月8日
最終確認日
2013年12月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。